NON-HODGKIN LYMPHOMA

This study tests a new treatment called CTX112 for people with B-cell cancers (like lymphoma or leukemia) that have not responded to standard therapy or have returned. CTX112 uses CRISPR gene editing to modify immune cells from a healthy donor, making them target and kill cancer …

This early-stage trial tests an oral drug called AS-1763 in about 120 adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or other B-cell non-Hodgkin lymphomas who have already tried at least two other treatments. The study aims to find the safest dose and check…

This early-phase trial tests a new approach for people with certain lymphomas that have come back or not responded to treatment. Researchers take immune cells from healthy donors, modify them to recognize and attack CD30-positive cancer cells, and add a molecule (C7R) to boost th…

This early-stage trial is testing whether combining two existing immunotherapy drugs (mosunetuzumab or glofitamab) with newer oral drugs (iberdomide and/or golcadomide) can safely treat B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. About 121 a…

This phase 2 trial tests a two-step stem cell transplant using lower doses of radiation and chemotherapy before the transplant. The goal is to reduce treatment-related deaths in people with various blood cancers like leukemia, lymphoma, and myeloma. About 63 participants will rec…

This study tests a new approach using immune cells from healthy donors, engineered to recognize and attack cancer cells. The target is chosen based on each participant's tumor profile. The trial includes 85 adults with advanced solid tumors that have not responded to standard tre…

This phase II trial is testing whether adding the JAK inhibitor ruxolitinib to the immunotherapy drug pembrolizumab is safe and effective for people with relapsed or refractory Hodgkin and non-Hodgkin lymphomas. The study will enroll 53 participants with specific lymphoma subtype…

This early-stage study tests a new type of stem cell transplant for children whose blood cancers or solid tumors have returned or are hard to treat. The transplant uses a half-matched donor and removes certain immune cells to lower the risk of graft-versus-host disease. A drug ca…

This early-phase trial is testing a treatment where a patient's own immune cells are modified in a lab to better recognize and attack cancer cells. It is for people with certain types of Non-Hodgkin lymphoma that have come back or not responded to standard treatments. The main go…

This study looks at the long-term safety of the drug pirtobrutinib in people with chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma (NHL) who were already in a previous trial. About 279 participants will continue their treatment or follow-up visits. The main goal is to t…

This phase 2 trial is testing a new formulation of the chemotherapy drug carmustine that doesn't contain ethanol, compared to the standard version that does. Both are used as part of the BEAM conditioning regimen before an autologous stem cell transplant in adults with Hodgkin or…

This early-stage trial tests a new biologic drug called PIC1 injection in 18 adults with relapsed or refractory B-cell non-Hodgkin lymphoma. The main goal is to check safety and find the right dose. Researchers will also see if the drug can shrink tumors. It is too soon to know i…

This early-phase study tests a new treatment for people with Hodgkin or non-Hodgkin lymphoma that has returned or not responded to standard therapy. The treatment uses the patient's own immune cells (T cells) that are modified in the lab to recognize and attack cancer cells carry…

This early-stage study is testing an experimental drug called CC312 in people with certain blood cancers (like lymphoma and leukemia) that have returned or stopped responding to standard treatments. The main goals are to check the drug's safety and find the right dose. About 44 a…

This study tests a new drug called BGB-16673 for people in China with certain blood cancers (B-cell malignancies) that have come back or not responded to treatment. The drug works by breaking down a protein that helps cancer cells grow. The trial has two parts: first, finding the…

This study tests a new treatment for people with advanced B-cell lymphoma or leukemia that has returned or not improved after standard therapy. Researchers take a patient's own T-cells, add a special receptor (CAR) that targets the CD19 protein on cancer cells, and also add extra…

This study tests a new drug called CHO-H01, alone or with another drug (lenalidomide), in people with a type of blood cancer called non-Hodgkin's lymphoma that has returned or not responded to prior treatments. The goal is to find a safe dose and see if the combination can shrink…

This early-phase study tests a new drug called KSV01 in 18 adults with relapsed or refractory diffuse large B-cell lymphoma, a type of blood cancer that has not responded to standard treatments. The main goal is to check the safety of the injection and find the best dose. Partici…

This early-phase trial tests a new drug, SGR-1505, in about 98 adults with various B-cell blood cancers (like lymphoma or leukemia) that have not responded to other treatments. The main goals are to find the safest dose and understand side effects. Participants will receive the d…

This study tests whether a cord blood transplant can help children and young adults (up to age 26) with blood cancers like leukemia and lymphoma. Participants receive the transplant as their first or second treatment. The main goal is to see how many are cancer-free one year afte…

This study is for adults with Non-Hodgkin lymphoma, a rare cancer of the immune cells. Researchers are testing a new drug called epcoritamab combined with other cancer medicines to see if the combinations are safe and help control the disease. About 496 people will take part at h…

This study tests a special cord blood transplant for people with high-risk blood cancers like leukemia and lymphoma. Participants get chemotherapy and radiation before the transplant to kill cancer cells and prepare the body. After the transplant, drugs are given to prevent the n…

This early-stage study tests a new drug called AXT-1003 in people with advanced non-Hodgkin lymphoma or solid tumors that have not responded to standard treatments. The main goal is to check the drug's safety and find the right dose. About 78 participants will take part in this o…

This early-stage study tests a new oral drug, LP-118, in up to 100 adults with blood cancers like lymphoma, leukemia, or myeloma that returned or didn't respond to prior therapy. The main goals are to find the safest dose and see if the drug can shrink tumors or slow the disease.…

This early-stage trial tests a new type of immune cell therapy (TmCD19-IL18 CAR T cells) for people with a blood cancer called non-Hodgkin lymphoma that has come back or not responded to standard treatment. The study aims to find the safest dose and see if the therapy can shrink …

This early-phase study tests a new type of immunotherapy called CD19x22 CAR T cells for teenagers and adults with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified to attack two targets on cancer …

This early-phase study tests a new treatment for adults with certain types of blood cancer (like lymphoma) that have come back or not responded to standard therapies. The treatment combines a targeted drug (pirtobrutinib) with specially engineered immune cells (CAR T-cells) desig…

This study provides unlicensed cord blood units for transplant to children and adults with blood cancers, immune disorders, and other serious diseases. The goal is to see how well patients recover their white blood cells after the transplant. By making more cord blood units avail…

This early-stage study tests a new treatment called GB5005 for people with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has returned or stopped responding to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize…

This early-phase study is testing whether a second infusion of the CAR T-cell therapy axicabtagene ciloleucel (Axi-Cel-2) is safe for adults with high-risk large B-cell lymphoma whose cancer came back or didn't respond to the first standard CAR T treatment. About 20 participants …

This early-phase study tests a new drug called JLM019 in adults with advanced solid tumors or lymphomas that have come back or not responded to treatment. The main goal is to find a safe dose and check for side effects. Participants receive weekly injections, and the study will m…

This early-phase study tests whether Darzalex Faspro can safely lower donor-specific antibodies (DSAs) in 8 adults with blood cancers or bone marrow failure who are at high risk of rejecting a stem cell transplant. The goal is to reduce DSA levels enough to allow the transplant t…

This study tests two different drug combinations to prevent graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body after a stem cell transplant. About 400 adults with blood cancers like leukemia or lymphoma will receive either thymogl…

This early-stage trial tests a new treatment called Azer-cel, a type of immune cell therapy made from donor cells, for adults with certain blood cancers that have come back or not responded to standard treatments. The goal is to see if it is safe and can shrink tumors or put the …

This study looks at the long-term safety of the drug pirtobrutinib in people with chronic lymphocytic leukemia or non-Hodgkin lymphoma. About 787 participants who completed an earlier pirtobrutinib study can join to keep receiving treatment or have follow-up visits. The main goal…

This study tests a new drug called CCS1477 in people with advanced blood cancers like leukemia, lymphoma, and multiple myeloma. The goal is to see if the drug is safe and can help control the disease. About 250 participants will receive the drug alone or with other treatments.

This program provides early access to an experimental drug called AVM0703 for people with various solid tumors and blood cancers, including hard-to-treat types like glioblastoma and metastatic breast cancer. It is available to patients in the US whose doctor requests it. So far, …

This study tests whether combining two oral drugs, pirtobrutinib and venetoclax, can control mantle cell lymphoma (MCL) in patients whose cancer has come back or hasn't responded to prior treatments. About 30 adults with confirmed MCL will take these pills to see how many achieve…

This early-stage trial tests whether adding the drug pomalidomide to standard chemotherapy (with or without rituximab) is safe and effective for people with HIV who have aggressive B-cell non-Hodgkin lymphoma. About 25 adults with high-risk features will receive up to 6 cycles of…

This study tests a modified stem cell transplant regimen for lymphoma patients at high risk of the cancer spreading to the brain. About 45 adults who have already responded to initial treatment will receive high-dose chemotherapy with thiotepa, etoposide, cytarabine, and melphala…

This early-phase study tests a new drug called SB-4826 in adults with advanced solid tumors or non-Hodgkin lymphoma. The main goal is to find a safe dose and see if the drug shrinks tumors. Some participants with lymphoma will also receive the drug combined with rituximab. The st…

This study tests whether adding the drug ibrutinib to standard chemotherapy can better control primary central nervous system lymphoma (PCNSL) in people who are not eligible for a stem cell transplant. About 30 adults aged 65 or older or with other health issues will receive the …

This study tests a new drug called AZD3470, alone or with other cancer drugs, in people with certain blood cancers like lymphoma. The goal is to see if it is safe and helps control the disease. About 161 adults and teens will take part. This is an early-phase trial, so the main f…

This study tests a new combination of drugs (linperlisib plus cyclophosphamide, prednisone, and thalidomide) in 180 adults with relapsed or refractory non-Hodgkin lymphoma. The goal is to see how well the treatment shrinks tumors and controls the disease. Participants must have c…

This study tests a stem cell transplant using a patient's own cells to treat Hodgkin and non-Hodgkin lymphoma, including in people with HIV. The goal is to see if a radiation-free preparation improves survival at 3 years. About 150 participants will be enrolled.

This study looks at whether a wearable device and a questionnaire can spot autonomic dysfunction—a condition affecting automatic body functions like heart rate—in survivors of childhood leukemia and lymphoma. Researchers will compare these remote methods to standard in-person tes…

This study tests whether a tailored physical activity program can help lymphoma and breast cancer patients preserve their exercise ability, heart function, memory, and quality of life while undergoing cancer treatment. About 110 adults aged 18-85 with Hodgkin or non-Hodgkin lymph…

This study is for people who received a Bristol-Myers Squibb CAR-T cell therapy (like Breyanzi or Abecma) and later developed a second cancer. Researchers will test samples of that second cancer to see if it contains any of the gene-modified cells from the original treatment. The…

This study aims to discover new genes that may cause certain cancers to run in families. Researchers will collect blood samples and health information from 1,500 people in families where multiple members have had cancer, especially childhood cancers. The goal is to build a regist…

This study is testing whether daily voice recordings can help doctors spot early signs of a brain-related side effect called ICANS in people receiving CAR T-cell therapy for non-Hodgkin lymphoma or multiple myeloma. About 20 participants will use their smartphones to record their…

This early-phase study is testing a new imaging agent called [68Ga]-pentixafor to see how well it shows up on PET/CT scans in people with certain blood cancers (like multiple myeloma and non-Hodgkin lymphoma) and rare immune cell tumors. About 30 participants will get the agent a…

This study looks at whether a tailored exercise program can help older blood cancer survivors slow down the aging process. Researchers will enroll 180 people aged 50 and older who have had blood cancer. The goal is to see if participants can stick with the exercise plan and if it…

This study looks at whether firefighters' exposure to dangerous chemicals on the job raises their risk of developing early signs of blood cancers. Researchers will follow 300 firefighters aged 40-49 from the Charlotte Fire Department who have at least 5 years of experience. The g…

This study looks at whether it's possible to measure how the body breaks down certain medicines in children and young adults (ages 6-25) with Hodgkin or non-Hodgkin lymphoma. Participants will take a small dose of a probe drug during routine hospital visits, and blood samples wil…

This study looks at whether peer education and support can help more adolescents and young adults (ages 15-39) living with HIV get screened for cancer and stick with their cancer treatment. Researchers will work with 4,100 participants in Zambia to improve early diagnosis and tre…

This study looks at how personal relationships and physical activity influence the quality of life of young adults (ages 18-39) who have been diagnosed with cancer. Researchers will track 250 participants over time to see how social connections and exercise habits change and affe…

This study follows 2,000 adults with newly diagnosed breast, colorectal, lung, melanoma, or lymphoma cancer who are receiving chemotherapy or immunotherapy. Researchers will track whether using cannabis or cannabinoids helps with symptoms like pain or nausea over time. No treatme…

This early-phase study tests a new PET imaging tracer called 64Cu-GRIP B in 32 adults with relapsed or refractory non-Hodgkin lymphoma who are receiving CAR-T therapy. The tracer aims to detect a protein (granzyme B) released by activated immune cells, which may help identify tum…